Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals has recently experienced an evaluation adjustment amid challenging financial performance in Q2 FY24-25, marked by declines in net sales and profit after tax. Despite these difficulties, the company maintains a strong long-term growth trajectory, although concerns about management efficiency and debt servicing persist.

Shukra Pharmaceuticals has recently experienced an evaluation adjustment reflecting its current market position. The company reported negative financial performance for Q2 FY24-25, with significant declines in net sales and profit after tax. Despite these challenges, it has shown healthy long-term growth and consistent stock performance.

Shukra Pharmaceuticals has achieved a new 52-week high of Rs. 233.5, reflecting strong performance in the Pharmaceuticals & Drugs sector. The stock has gained 4.01% over the past two days and boasts an impressive annual return of 572.43%, significantly surpassing the Sensex's growth.

Shukra Pharmaceuticals has achieved a new 52-week high of Rs. 233.5, reflecting strong performance in the Pharmaceuticals & Drugs sector. The stock has gained 4.01% over the past two days and boasts an impressive annual return of 572.43%, significantly surpassing the Sensex's growth.

Shukra Pharmaceuticals has achieved a new 52-week high, reflecting a strong upward trend and significant outperformance compared to its sector. The stock has shown impressive momentum with an 85.17% return over the past 21 days and an extraordinary one-year performance of 627.14%, highlighting its strong market position.

Shukra Pharmaceuticals has achieved a new 52-week high, reflecting strong market activity and a remarkable 90.65% return over the past 21 days. The company has significantly outperformed its sector and the Sensex over the past year, showcasing its robust market position and upward trend in stock performance.

Shukra Pharmaceuticals has achieved a new 52-week high of Rs. 216, reflecting significant momentum with a 21-day consecutive gain and a 92.51% return. Over the past year, the stock surged by 587.62%, greatly exceeding the Sensex's 8.94% increase, highlighting its volatility and potential in the pharmaceuticals sector.

Shukra Pharmaceuticals has achieved a new 52-week high of Rs. 215.9, showcasing strong performance in the pharmaceuticals sector. The stock has outperformed its sector and demonstrated significant annual growth of 573.63%, highlighting its robust market presence and attracting considerable investor interest.

Shukra Pharmaceuticals has achieved a 52-week high of Rs. 211.7, reflecting a remarkable 108% increase in returns over the past 21 days. The company has outperformed its sector and recorded a substantial 560.53% annual growth, significantly exceeding the Sensex's performance.

Shukra Pharmaceuticals has achieved a 52-week high of Rs. 207.55, reflecting strong performance with a 114.1% increase over the past 21 days. The stock has consistently traded above key moving averages and has recorded a remarkable 547.58% annual growth, significantly surpassing the Sensex's performance.

Shukra Pharmaceuticals achieved a 52-week high of Rs. 203.5 on January 17, 2025, reflecting a strong upward trend with a 120.41% gain over the past 21 days. The stock has significantly outperformed its sector and delivered an impressive annual return of 522.09%.

Shukra Pharmaceuticals has achieved a new 52-week high, reaching Rs. 199.55 on January 16, 2025. The stock has shown remarkable growth, with a 126.92% return over the past 21 days and an impressive 497.90% annual return, significantly outperforming the broader market.

Shukra Pharmaceuticals has achieved a 52-week high of Rs. 195.65, reflecting strong market interest and a remarkable 144.72% return over the past 21 days. The company has outperformed its sector and delivered an impressive 474.60% annual return, highlighting its significant growth in the pharmaceuticals industry.

Shukra Pharmaceuticals has achieved a 52-week high of Rs. 191.85, outperforming its sector in today's trading. The stock has shown a remarkable 162.74% increase over the past 21 days and an impressive annual return of 452.28%, significantly exceeding the Sensex's modest gains.

Shukra Pharmaceuticals achieved a 52-week high of Rs. 188.1 on January 13, 2025, showcasing exceptional performance by outperforming its sector. Over the past year, the stock has surged by 441.49%, highlighting its strong position in the pharmaceuticals industry compared to the Sensex's modest increase.

Shukra Pharmaceuticals has recently been added to MarketsMOJO's list following a revision in its score, reflecting its impressive performance metrics. The stock reached a new 52-week high and has outperformed its sector significantly, showcasing strong growth trends and consistent upward momentum over the past year.

Shukra Pharmaceuticals has achieved a notable milestone, reaching a 52-week high and demonstrating exceptional performance by surpassing its sector. Following a recent evaluation, the stock has seen a revision in its score, reflecting its strong market position and impressive annual returns. Shukra Pharmaceuticals has also been added to MarketsMOJO's list, underscoring its robust performance indicators.

Shukra Pharmaceuticals has recently undergone a revision in its score by MarketsMOJO, reflecting the company's challenging financial landscape. Despite a significant drop in net sales and negative operating cash flow for the second quarter of FY24-25, the stock has been added to MarketsMOJO's list, highlighting its long-term growth potential and bullish technical indicators. However, concerns remain regarding its low return on equity and high debt levels.

Shukra Pharmaceuticals has recently been added to MarketsMOJO's list following a notable revision in its score, reflecting its impressive performance metrics. The stock reached a new 52-week high and has significantly outperformed its sector, showcasing strong annual growth and consistent trading above key moving averages.